Abstract 7287: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy in Atrial Fibrillation with Stable Coronary Artery Disease: An Updated Systematic Review and Meta Analysis
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.7287 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Aseed Mestarihi und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Patients with atrial fibrillation and stable coronary artery disease require long-term antithrombotic therapy that balances ischemic protection with bleeding risk. Although guidelines favor oral anticoagulation monotherapy beyond the early post-revascularization period, clinical practice remains variable. Prior randomized trial meta analyses did not include the most recently published trial evidence. Hypothesis: We hypothesized that single antithrombotic therapy (SAT) with oral anticoagulation monotherapy reduces bleeding without increasing ischemic events compared with dual antithrombotic therapy (DAT) with oral anticoagulation plus antiplatelet therapy.
Methods
We performed an updated systematic review and meta analysis of randomized controlled trials comparing single versus dual antithrombotic therapy in adults with atrial fibrillation and stable coronary artery disease. PubMed/MEDLINE, Embase, Scopus, and Cochrane CENTRAL were searched from inception through November 24, 2025. Two reviewers independently screened studies and extracted data. Co-primary outcomes were all cause mortality and major bleeding. Secondary outcomes included cardiovascular death, myocardial infarction, ischemic stroke, systemic embolism, net adverse clinical events, and clinically relevant non major bleeding. Pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated.
Results
Five randomized trials including 5,052 patients were analyzed; 2,531 were assigned to SAT and 2,521 to DAT. In time to event analyses, SAT was not associated with a significant difference in all-cause mortality (HR, 0.78; 95% CI, 0.60-1.02; p=0.06), cardiovascular death (HR, 0.75; 95% CI, 0.53-1.08), ischemic stroke (HR, 0.94; 95% CI, 0.62-1.44), or myocardial infarction (HR, 1.37; 95% CI, 0.73-2.55). SAT significantly reduced major bleeding (HR, 0.55; 95% CI, 0.42-0.72; p
Zitieren
APA
Mestarihi, A., Rayyan, A., Assad, A., Othman, M., Kawtharany, H., Haddad, E., Mansour, M., Alqudah, Q., & tong, A. (2026). Abstract 7287: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy in Atrial Fibrillation with Stable Coronary Artery Disease: An Updated Systematic Review and Meta Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.7287
Vancouver
Mestarihi A, Rayyan A, Assad A, Othman M, Kawtharany H, Haddad E, et al. Abstract 7287: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy in Atrial Fibrillation with Stable Coronary Artery Disease: An Updated Systematic Review and Meta Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.7287
BibTeX
@article{Mestarihi2026,
author = {Mestarihi, Aseed and Rayyan, Abdallah and Assad, Ahmad and Othman, Malek and Kawtharany, Hassan and Haddad, Enad and Mansour, Mohamad and Alqudah, Qusai and tong, ann},
title = {Abstract 7287: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy in Atrial Fibrillation with Stable Coronary Artery Disease: An Updated Systematic Review and Meta Analysis},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.7287}
}
EUVIMED